The size of the European antimicrobial susceptibility testing market was worth USD 1.27 billion in 2022. This value is expected to grow at a CAGR of 5.62% from 2022 to 2027 and be worth USD 1.68 billion by 2027.
Several diseases that are caused by bacteria have been found in Europe. These diseases are spread through poor water and dirty places. Doctors can use special tests to help fight these diseases to see which medicines will work best. These tests are critical, are used in many hospitals, and are expected to help the antimicrobial susceptibility testing market grow in the European region.
The growth of the antimicrobial susceptibility testing market in Europe is mainly due to the increased use of this testing by biopharmaceutical, biotechnological, and pharmaceutical companies. Additionally, the market for mouth ulcer treatment is expected to grow due to increased focus on drug research, the emergence of new diseases, the increasing prevalence of chronic conditions, and the growing population.
The European market for antimicrobial susceptibility testing is expected to continue growing due to the increasing prevalence of hospital-acquired infections (HAIs), the expansion of the patient population, particularly in developing countries, and increased government awareness of the need to address antimicrobial resistance. Testing is also helpful for evaluating treatment services provided by hospitals, clinics, and national infectious disease control and prevention programs. In addition, researchers have also recently been required to conduct ongoing monitoring for resistance patterns due to changes in microbial genomes.
However, government regulations may inhibit the growth of this market in Europe. During the early stages of the COVID-19 pandemic, the antimicrobial resistance (AMR) issue received relatively little attention. Prescribers administered antibiotics indiscriminately to treat and prevent suspected bacterial co-infections because there was no known therapy for COVID-19. Even in places where antimicrobial stewardship (AMS) systems were already in place, there were issues with the way antibiotics were used during the pandemic. Additionally, with the shift of healthcare resources to the pandemic response, AMR surveillance and AMS were de-prioritized, which hindered market growth by limiting AMR surveillance. However, the market for antimicrobial susceptibility testing has been picking up again as the pandemic slows down and the irrational use of antimicrobials during the pandemic is addressed.
COVID-19 impact on the Europe AST market:
The COVID-19 pandemic has significantly impacted the European antimicrobial susceptibility testing (AST) market. During the early stages of the pandemic, there was a focus on treating and preventing suspected bacterial co-infections with antibiotics, leading to an increase in the use of AST to determine the appropriate antimicrobial treatment. However, the shift of healthcare resources to the pandemic response and the de-prioritization of antimicrobial resistance (AMR) surveillance and antimicrobial stewardship (AMS) during this time hindered market growth by limiting AMR surveillance.
As the pandemic progressed and the irrational use of antimicrobials during the pandemic was addressed, the market for AST picked up again. Furthermore, the increased prevalence of hospital-acquired infections (HAIs) and the expansion of the patient population, particularly in developing countries, have also contributed to the growth of the AST market. In addition, the availability of manual and automated AST products that provide faster and more accurate results is an emerging opportunity for key market players, driving market expansion and offering significant growth opportunities in the European region.
This research report on the European antimicrobial susceptibility testing market has been segmented and sub-segmented into the following categories.
By Product:
Based on the product, the automated laboratory instruments segment accounted for the major share of the European antimicrobial susceptibility testing market in 2021. The increasing efforts of major market participants in the regional market are primarily propelling the segment's growth.
By Application:
The clinical diagnostics segment led the market in 2021. The growing patient population suffers from infectious diseases, and hospital-acquired infections significantly promote the segment's growth rate.
By End-User:
The hospitals and diagnostic centers segment held the dominating share of the European AST market in 2021, and the domination is expected to continue throughout the forecast period.
By Country:
Europe is expected to experience healthy growth during the forecast period due to increased efforts by key market players in the region. The overuse and misuse of antibiotics also cause antimicrobial resistance (AMR). Additionally, there are opportunities for market growth in emerging markets with significant potential due to better healthcare infrastructure, increased unmet healthcare needs, and increased antimicrobial resistance in populations. The market for antimicrobial susceptibility testing is also expected to expand due to the availability of manual and automated products that provide more accurate results in a shorter time. This is expected to provide significant opportunities for market growth in the European region during the forecast period.
In 2021, Germany dominated the European market due to an increase in epidemic and pandemic events. In addition, healthcare companies in Germany are also showing an increased interest in antimicrobial susceptibility testing due to a greater demand for automated products such as AST cards, AST panels, and high-tech automated systems that provide higher accuracy, faster processing, and improved workflow. This leads to an increase in the use of automated systems in pharmaceutical and biotechnology companies, indicating that the industry has significant potential for growth.
KEY MARKET PLAYERS:
Companies playing a vital role in the European antimicrobial susceptibility testing market profiled in this report are Danaher Corporation, Becton, Dickinson, and Company., Bio-Rad Laboratories, Inc., Thermo Fisher Scientific Inc., HiMedia Laboratories Pvt. Ltd., Merlin Diagnostika GmbH, bioMerieux S.A., Merck KGaA, Accelerate Diagnostics, Inc., and Creative Diagnostics.
Related Reports
Access the study in MULTIPLE FORMATS
Purchase options starting from $ 1400
Didn’t find what you’re looking for?
TALK TO OUR ANALYST TEAM
Need something within your budget?
NO WORRIES! WE GOT YOU COVERED!
Call us on: +1 888 702 9696 (U.S Toll Free)
Write to us: [email protected]
Reports By Region